Antitrust regulators shouldn't clear Novo Holdings' planned acquisition of Catalent, Roche CEO Thomas Schinecker said ...

Thermo Fisher told investors it is ready to shut the door on 2024, anticipating biotech funding to improve and lingering ...

Alto Neuroscience’s stock tumbled 60% on Wednesday morning, the day after the company said a mid-stage trial for its oral ...

A venture capital firm that seeks to digitize the life sciences ecosystem has plans for a $500 million follow-up fund, ...

A nimble Houston startup has raised a concise $28.4 million Series A to start a mid-stage trial. The company, named March ...

The UK medicines authority approved Eli Lilly’s Alzheimer’s drug Kisunla on Wednesday, making it the third major market to ...

Roche’s competition in the eye disease space is intensifying with Renegeron’s high-dose Eylea and looming biosimilar ...

Merck is acquiring a startup spun out of Yale called Modifi Bio, which has developed a suite of molecules against ...

Eccogene's $60M milestone from AstraZeneca: The payment arrived after Eccogene met several milestones, including dosing the first ...

Amgen is moving forward with the launch of Pavblu, its biosimilar to Regeneron's blockbuster Eylea, following an appeals ...

The eye drop maker Ocuphire Pharma and startup Opus Genetics are merging in an all-stock deal, the companies told Endpoints ...

Starboard Value, the activist investor pushing for changes at Pfizer, unveiled its goals for another healthcare company — ...